Bristol-Myers Squibb Overview
- Year Founded
-
1887
- Status
-
Public
- Employees
-
34,100
- Stock Symbol
-
BMY
- Investments
-
137
- Share Price
-
$56.29
- (As of Friday Closing)
Bristol-Myers Squibb General Information
Description
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Contact Information
Website
www.bms.comCorporate Office
- Route 206 & Province Line Road
- 14th Floor
- Princeton, NJ 08543
- United States
Corporate Office
- Route 206 & Province Line Road
- 14th Floor
- Princeton, NJ 08543
- United States
Bristol-Myers Squibb Timeline
Bristol-Myers Squibb Stock Performance
As of 17-Jan-2025, Bristol-Myers Squibb’s stock price is $56.29. Its current market cap is $114B with 2.03B shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $56.29 | $56.38 | $39.35 - $61.08 | $114B | 2.03B | 10.6M | -$3.58 |
Bristol-Myers Squibb Financials Summary
As of 30-Sep-2024, Bristol-Myers Squibb has a trailing 12-month revenue of $47.4B.
|
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 152,302,427 | 136,049,420 | 184,123,237 | 168,486,862 |
| Revenue | 47,435,000 | 45,006,000 | 46,159,000 | 46,385,000 |
| EBITDA | 5,132,000 | 19,417,000 | 19,232,000 | 20,191,000 |
| Net Income | (7,258,000) | 8,025,000 | 6,327,000 | 6,994,000 |
| Total Assets | 93,670,000 | 95,159,000 | 96,820,000 | 109,314,000 |
| Total Debt | 51,400,000 | 41,464,000 | 40,717,000 | 45,596,000 |
Bristol-Myers Squibb Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Bristol-Myers Squibb Comparisons
Industry
Financing
Details
Bristol-Myers Squibb Competitors (26)
One of Bristol-Myers Squibb’s 26 competitors is Eli Lilly and Company, a Corporation company based in Indianapolis, IN.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | Corporation | Indianapolis, IN | ||||
| Amgen | Formerly PE-Backed | Thousand Oaks, CA | ||||
| Gilead Sciences | Formerly VC-backed | Foster City, CA | ||||
| AbbVie | Corporation | North Chicago, IL | ||||
| Merck & Co. | Corporation | Rahway, NJ |
Bristol-Myers Squibb Patents
Bristol-Myers Squibb Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240390284-A1 | Ionizable lipids | Pending | 25-May-2023 | ||
| EP-4490703-A1 | Medical imaging analysis using self-supervised learning | Pending | 20-Apr-2023 | ||
| EP-4490166-A1 | Transient expression of therapeutic proteins | Pending | 09-Mar-2023 | ||
| US-20240290435-A1 | Knowledge lens for multidimensional domains | Pending | 28-Feb-2023 | ||
| US-20240274286-A1 | Clinical outcome prediction by application of machine learning models to clinical data | Pending | 09-Feb-2023 | G06N3/08 |
Bristol-Myers Squibb Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Bristol-Myers Squibb Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Bristol-Myers Squibb Investments & Acquisitions (137)
Bristol-Myers Squibb’s most recent deal was a Early Stage VC with Light Horse Therapeutics for . The deal was made on 09-Jan-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Light Horse Therapeutics | 09-Jan-2025 | Early Stage VC | Biotechnology | ||
| ArsenalBio | 04-Sep-2024 | Later Stage VC | Drug Discovery | ||
| Abata Therapeutics | 15-Aug-2024 | Early Stage VC | Biotechnology | ||
| Autobahn Therapeutics | 24-Jul-2024 | Later Stage VC | Biotechnology | ||
| Envisagenics | 04-Jun-2024 | Later Stage VC | Discovery Tools (Healthcare) |
Bristol-Myers Squibb ESG
Risk Overview
Risk Rating
Updated June, 19, 2024
21.2 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,104
Rank
Percentile
Pharmaceuticals
Industry
of 851
Rank
Percentile
Biotechnology
Subindustry
of 367
Rank
Percentile
Bristol-Myers Squibb Exits (37)
Bristol-Myers Squibb’s most recent exit was on 23-Jan-2024 from Mirati Therapeutics. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Mirati Therapeutics | 23-Jan-2024 | Completed |
|
||
| Zenas BioPharma | 05-Sep-2023 | Completed |
|
||
| Immatics | 21-Jul-2023 | Completed |
|
||
| Metagenomi | 05-Jan-2023 | Completed |
|
||
| Cardior | 25-Aug-2021 | Later Stage VC | Completed |
|
Affiliates
Subsidiaries (10)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| RayzeBio | San Diego, CA | 2020 | |
| IFM Therapeutics | Boston, MA | 2015 | |
| Systimmune | Redmond, WA | 2014 | |
| Turning Point Therapeutics | San Diego, CA | 2013 | |
| MyoKardia | Brisbane, CA | 2012 |
Bristol-Myers Squibb FAQs
-
When was Bristol-Myers Squibb founded?
Bristol-Myers Squibb was founded in 1887.
-
Where is Bristol-Myers Squibb headquartered?
Bristol-Myers Squibb is headquartered in Princeton, NJ.
-
What is the size of Bristol-Myers Squibb?
Bristol-Myers Squibb has 34,100 total employees.
-
What industry is Bristol-Myers Squibb in?
Bristol-Myers Squibb’s primary industry is Drug Discovery.
-
Is Bristol-Myers Squibb a private or public company?
Bristol-Myers Squibb is a Public company.
-
What is Bristol-Myers Squibb’s stock symbol?
The ticker symbol for Bristol-Myers Squibb is BMY.
-
What is the current stock price of Bristol-Myers Squibb?
As of 17-Jan-2025 the stock price of Bristol-Myers Squibb is $56.29.
-
What is the current market cap of Bristol-Myers Squibb?
The current market capitalization of Bristol-Myers Squibb is $114B.
-
What is Bristol-Myers Squibb’s current revenue?
The trailing twelve month revenue for Bristol-Myers Squibb is $47.4B.
-
Who are Bristol-Myers Squibb’s competitors?
Eli Lilly and Company, Amgen, Gilead Sciences, AbbVie, and Merck & Co. are some of the 26 competitors of Bristol-Myers Squibb.
-
What is Bristol-Myers Squibb’s annual earnings per share (EPS)?
Bristol-Myers Squibb’s EPS for 12 months was -$3.58.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
